Here are the 10-Q quarterly reports from Latigo Biotherapeutics, Inc. (LTGO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LTGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LTGO filings page.
Latigo Biotherapeutics, Inc. (LTGO) completed its IPO in August 2026, issuing 22,080,000 common shares at $18.00 per share and receiving approximately $364.4 million in net proceeds. The total included 2,880,000 additional shares purchased through the underwriters’ fully exercised option; underwriting discounts, commissions and other offering costs were approximately $33.1 million.
As of September 30, 2026, cash and cash equivalents were $401.2 million and the accumulated deficit was $312.8 million. Third-quarter net loss was $20.949 million, compared with $24.796 million in 2025; research and development expense was $17.502 million, versus $22.097 million. For the first nine months, net cash used in operating activities was $67.9 million, compared with $62.6 million in 2025. Latigo said its cash was sufficient to fund operating plans for at least the 12-month period following issuance of the financial statements, alleviating prior substantial doubt about its ability to continue as a going concern.
Latigo is a clinical-stage biopharmaceutical company with onzotrigine and LTG-321 in clinical development. It disclosed a material weakness in internal control over financial reporting.
Latigo Biotherapeutics, Inc. (LTGO), a clinical-stage biotechnology company developing non-opioid pain medicines, reported continued operating losses and significant cash use for the quarter ended June 30, 2026. Total assets were $64.8 million, including $55.0 million of cash and cash equivalents.
The company recorded a net loss of $25.8 million for the quarter and $48.8 million for the first six months of 2026, similar to the prior-year periods, driven mainly by research and development expenses of $38.9 million year-to-date. Net cash used in operating activities was $48.4 million for the six-month period, resulting in a growing accumulated deficit of $291.9 million and a stockholders’ deficit of $276.1 million.
Liquidity was strengthened after period-end: in August 2026 Latigo completed an IPO, issuing 22,080,000 shares at $18.00 per share for net proceeds of $363.9 million, and its outstanding redeemable convertible preferred stock and $35.2 million of convertible notes (principal plus interest) converted into common stock. Management states that, with IPO proceeds, existing cash is expected to fund operations for at least 12 months from issuance of these financial statements, alleviating prior substantial doubt about going concern.